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Abstract
Background: Simvastatin therapy for patients with acute respiratory distress syndrome (ARDS) has been shown to
be safe and associated with minimal adverse effects, but it does not improve clinical outcomes. The aim of this
research was to report on mortality and cost-effectiveness of simvastatin in patients with ARDS at 12 months.
Methods: This was a cost-utility analysis alongside a multicentre, double-blind, randomised controlled trial carried out in
the UK and Ireland. Five hundred and forty intubated and mechanically ventilated patients with ARDS were randomly
assigned (1:1) to receive once-daily simvastatin (at a dose of 80 mg) or identical placebo tablets enterally for up to 28 days.
Results: Mortality was lower in the simvastatin group (31.8%, 95% confidence interval (CI) 26.1–37.5) compared to the
placebo group (37.3%, 95% CI 31.6–43.0) at 12 months, although this was not significant. Simvastatin was associated with
statistically significant quality-adjusted life year (QALY) gain (incremental QALYs 0.064, 95% CI 0.002–0.127) compared to
placebo. Simvastatin was also less costly (incremental total costs –£3601, 95% CI –8061 to 859). At a willingness-to-pay
threshold of £20,000 per QALY, the probability of simvastatin being cost-effective was 99%. Sensitivity analyses indicated
that the results were robust to changes in methodological assumptions with the probability of cost-effectiveness never
dropping below 90%.
Conclusion: Simvastatin was found to be cost-effective for the treatment of ARDS, being associated with both a
significant QALY gain and a cost saving. There was no significant reduction in mortality at 12 months,
Trial registration: ISRCTN, 88244364. Registered 26 November 2010.
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Background
The acute respiratory distress syndrome (ARDS) is a clin-
ical syndrome characterised by life-threatening respiratory
failure requiring mechanical ventilation. ARDS affects all
age groups; it has a high mortality [1, 2] and causes a
long-term reduction in quality of life for survivors [3].
ARDS has significant resource implications, prolonging
intensive care unit (ICU) and hospital stay, and requiring
rehabilitation in the community [4]. The average cost per
ICU bed day in the UK National Health Service (NHS) ex-
ceeds £1200, and the delivery of critical care to patients
with ARDS accounts for an important proportion of ICU
capacity. Only 54% of survivors are able to return to work
12 months after hospital discharge [5].
The HARP-2 trial [5, 6] tested the hypothesis that treat-
ment with enteral simvastatin 80 mg daily would improve
clinical outcomes in patients with ARDS compared to pla-
cebo. The clinical findings [6] reported that simvastatin
therapy was safe and associated with minimal adverse ef-
fects, but it did not improve clinical outcomes for patients
with ARDS assessed in terms of ventilator-free days (VFDs),
non-pulmonary organ failure-free days, and 28-day
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mortality. However, decisions on how resources should be
allocated to maximise the health of the population are
increasingly reliant on evidence of cost-effectiveness. The
National Institute for Health and Care Excellence (NICE)
[7] recommend that the effect on health-related quality of
life (HRQoL) of an intervention is also quantified to enable
the calculation of quality-adjusted life years (QALYs) and
the cost per QALY.
Few studies have assessed the cost-effectiveness analyses
of treatments for ARDS within the context of a randomised
controlled trial [8–10]. CESAR [8] and OSCAR [9] com-
pared conventional ventilator support with an alternative
device: extracorporeal membrane oxygenation (ECMO)
and high-frequency oscillation ventilation (HFOV), respect-
ively. BALTI-2 [10] compared the impact of an intravenous
infusion of salbutamol with placebo. In all cases, the
within-trial cost per QALY estimates far exceeded the
£20,000 threshold of NICE.
The aim of this paper was to report on the mortality
and cost-effectiveness of enteral simvastatin in patients
with ARDS at 12 months.
Methods
Study design
The HARP-2 trial has been described in detail elsewhere
[6, 11]. In brief, this was a multicentre, double-blind,
randomised control trial which recruited 540 adult pa-
tients from general ICUs in 40 hospitals in the UK and
Ireland. Patients were eligible if they were intubated and
mechanically ventilated and were within 48 h of onset of
ARDS. Patients were randomly assigned (1:1) to receive
once-daily simvastatin (at a dose of 80 mg) or identical
placebo tablets enterally for up to 28 days. The Northern
Ireland Clinical Trials Unit (NICTU) co-ordinated the
overall study.
The cost-effectiveness of simvastatin compared to pla-
cebo was assessed using a cost-utility analysis (CUA)
conducted alongside HARP-2 following the guidelines
for health technology assessment in the UK [7]. The
analysis was performed from the perspective of the Na-
tional Health Service and Personal Social Services, and
the health outcome used in the CUA was the QALY.
The time horizon for the analysis was 12 months. The
mortality for all patients at 12 months was also reported.
Data collection
Data from Health and social care service use relating to
primary hospital admission of patients were collected
prospectively via the case report form until primary hos-
pital discharge or death. Service use of patients after
hospital discharge until 12 months post-randomisation
was collected retrospectively via questionnaires posted
out to surviving patients at 6 and 12 months. Medication
use other than the study drug was not included in the
economic analysis to minimise the burden of recall on
patients. Mortality status was established via the re-
search site or general practitioner for patients recruited
in Northern Ireland and via NHS Digital (Reference
number MR1294) for patients recruited in England,
Scotland, and Wales. Individual-level resource use was
combined with unit costs to estimate costs for each
participant. Unit costs were obtained from publicly
available sources and set at 2013–2014 prices (Table 1)
[12–14, 24].
The HRQoL of patients was measured at discharge,
and at 3, 6, and 12 months using the generic EuroQol
Five Dimension (Three Level) (EQ-5D-3L) [15], and the
UK social preference weights were used to obtain single
utility values from the responses [16]. The EQ-5D is the
NICE [7] preferred measure of HRQoL for economic
evaluations and has been used previously in the critically
ill [8–10]. As patients were unconscious at baseline, the
utility value for an unconscious state (–0.402) was used;
this was in keeping with previous economic evaluations
of therapies for patients with ARDS [9, 10]. The area-
under-the-curve method was used to estimate patient-
specific QALYs accrued over the study period. Since pa-
tients still in hospital at 3 months were not administered
the EQ-5D-3L and the timing of the discharge EQ-5D-
3L varied, QALYS were calculated using only the base-
line, 6-, and 12-month EQ-5D-3L values.
Statistical analysis
The difference in mortality between groups was analysed
using the risk ratio and p value from Fishers’ exact test.
Time-to-event (death) data were presented using a
Kaplan-Meier plot.
The cost-utility analysis included only patients with
complete data on costs and QALYs in order to maintain
the correlation structure of the data. Mean imputation was
used for missing service use data in cases where the patient
reported using a care service (e.g. carer, home help, deliv-
ered meals) but did not provide the number of contacts per
week. Death was not considered a censoring event and pe-
riods after death were counted as observations with known
outcome [17]. In practice, this meant that an EQ-5D-3L
utility of zero was assigned for the time points after death.
For patients who had died in hospital, costs after hospital
discharge until 12 months follow-up were considered to be
zero. For patients who were discharged from hospital but
were dead at 28 days we also assumed their costs after hos-
pital discharge until 12 months to be zero. This was an ac-
ceptable assumption since, of the patients who were dead
at 28 days (24.5%; 132/539), only two patients were dis-
charged from hospital and they both subsequently died
within 2 weeks of discharge. For patients who were dead at
6 months, costs from 6 to 12 months were considered to
be zero. In some cases we could not assign zero costs to all
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Table 1 Unit costs (UK £) of health service contacts
Resource item Unit cost (£) Source
Primary admission
Intensive care level 1 day 696.12 NHS reference costs 2013–2014 (XC07Z) adult critical care [12]
Intensive care level 2 day 932.10 NHS reference costs 2013–2014 (XC06Z) adult critical care [12]
Intensive care level 3 day 1440.64 NHS reference costs 2013–2014 (XC01Z-XC05Z weighted average) adult critical care [12]
Other intensive care unit day 1228.65 NHS reference costs 2013–2014 (XC01Z-XC07Z weighted average) adult critical care [12]
High dependency unit day 932.10 NHS reference costs 2013–2014 (XC06Z) adult critical care [12]
Ward bed day 437.00 NHS reference costs 2013–2014 (VC40Z) rehabilitation for respiratory disorders [12]
Simvastatin 80 mg tablets 28 tabs/pack 2.02 National Health Service England and Wales (2014) NHS electronic drug tariff
(online; accessed 24 June 2015) [14]
Other hospital services
Non-specific ward days 483.04 NHS reference costs 2013–2014 (weighted average length of stay and cost of
non-elective long stays ) [12]
Outpatient attendance 109.00 Unit costs of health and social care 2014 p.111 [13]
Attendance at Accident and Emergency
department
233.00 Unit costs of health and social care 2014 p.111 (see and treat and convey) [13]
Community health services
GP surgery consultation 46.00 Unit costs of health and social care 2014 p.195 [13]
GP telephone consultation 28.00 Unit costs of health and social care 2014 p.195 [13]
GP home consultation 115.00 Unit costs of health and social care 2013 p.191 (inflated using the hospital
and community health services index) [24]
GP out of hours consultation 115.00 Unit costs of health and social care 2013 p.191 (home visit unit cost assumed as above) [24]
GP nurse surgery consultation 13.70 Unit costs of health and social care 2014 p.192 (per 15.5 min surgery consultation) [13]
GP nurse telephone consultation 4.85 Unit costs of health and social care 2014 p.192 (per 7.1 min telephone consultation)* [13]
GP nurse home visit 24.29 Unit costs of health and social care 2014 p.192 (per 15.5 min consultation and 12 min
travel assumed*) [13]
District nurse home visit 39.00 Unit costs of health and social care 2014 p.187 [13]
Social worker visit 79.00 Unit costs of health and social care 2014 p.206 (per 1 h cost assumed to include travel) [13]
Physiotherapist visit 51.00 Unit costs of health and social care 2014 p.179 [13]
Occupational therapist visit 77.00 Unit costs of health and social care 2014 p.180 [13]
Dietician visit 37.00 Unit costs of health and social care 2014 p.238 [13]
Nurse specialist visit 74.00 Unit costs of health and social care 2014 p.190 (per 1 h cost assumed to include travel) [13]
Rapid response/ acute care episode 182.00 Unit costs of health and social care 2013 p.111 (inflated using the hospital and
community health services index) [24]
Psychotherapy/counselling 50.00 Unit costs of health and social care 2014 p.51 [13]
Day centre 38.00 Unit costs of health and social care 2014 p.38 (per client session) [13]
Care services
Home help/care worker 17.00 Unit costs of health and social care 2014 p.210 (per 1 h cost assumed to include travel) [13]
Delivered meals 6.60 Unit costs of health and social care 2014 p.127 (per meal) [13]
Nursing home 511.00 Unit costs of health and social care 2014 p.33 (per week) [13]
Respite 511.00 Nursing home cost assumed as above
Residential care home 493.00 Unit costs of health and social care 2014 p.34 (weekly) [13]
Sheltered housing 443.00 Unit costs of health and social care 2014 p.39 (extra care housing for older people, weekly) [13]
*General practitioner (GP) time estimates assumed when not available for GP nurse
NHS National Health Service
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periods after death. This was the case for patients who were
discharged from hospital, alive at 28 days but were dead at
6 months; costs from discharge to 6 months were consid-
ered to be missing as no information was available on their
use of resources in the period up to their death. The same
was true for patients alive at 6 months but dead at
12 months; costs from 6 to 12 months were treated as
missing. Costs and QALYs were not discounted as the time
horizon of the study was 12 months.
Descriptive statistics were used to summarise the
health service resource use and associated costs for the
primary admission, discharge to 6 months and 6 to
12 months, EQ-5D-3L utilities, and QALYs. Significance
was judged where the confidence intervals (CIs) of dif-
ferential means excluded zero or p < 0.05.
The mean difference in cost and QALYs between groups
was estimated and the incremental cost-effectiveness ratio
(ICER) calculated (if appropriate) to estimate the cost per
QALY. Sampling uncertainty around the cost and QALY
estimates was investigated using non-parametric bootstrap-
ping. This involved re-sampling (with replacement) cost
and QALY pairs from the original sample to generate 1000
replicates of mean differences in cost and QALYs. These
were then plotted on the cost-effectiveness plane to display
their joint distribution. The resulting scatter plot was used
to derive the cost-effectiveness acceptability curve (CEAC)
by calculating the proportion of the ICER replicates which
would be considered cost-effective at various thresholds of
willingness-to-pay (WTP) for an additional QALY. In gen-
eral, NICE [18] consider interventions with an ICER of less
than £20,000 to be cost-effective. All analyses were per-
formed using Stata 12/IC for Windows®.
CEACs were also constructed for the following sensi-
tivity analyses:
1. Multiple regression was used to estimate the mean
difference between groups for total health service
costs and QALYs after adjusting for the baseline
variables of age, the Acute Physiology and Chronic
Health Evaluation (APACHE) II score, and
vasopressor requirement.
2. Missing total cost and QALY data points were filled
simultaneously using multiple imputation by chained
equations and predictive mean matching to generate
five imputed datasets. Treatment group, baseline
APACHE II score, age, vasopressor requirement at
baseline, mortality at 28 days and mortality at
12 months, and primary admission costs were
entered into the model as predictors of missing data.
3. Multiple imputation and adjustment for baseline
variables simultaneously.
4. Death was treated as a censored event, i.e. data were
considered to be missing for patients who had died
over the study period.
5. Mean imputation was not used for missing care
service data, i.e. treated as missing.
6. Discharge and 3-month EQ-5D-3L data were used
in the calculation of QALYs where available.
All curves were constructed regardless of whether the
cost and effect differences were statistically significant,
in keeping with current health economic practice. Sam-
ple size was based on the primary outcome (VFDs) and
not on the basis of mortality alone, costs, QALYs, or
cost-effectiveness.
Results
Five hundred and forty patients were randomised, 259 to
receive simvastatin and 281 to receive placebo. Five pa-
tients withdrew consent over the study but only one did
not give permission for the use of their anonymised data
collected prior to withdrawal. Thus, 539 patients were
eligible for inclusion in the analysis. Mortality was lower
in the simvastatin group (31.8%, 95% CI 26.1–37.5) com-
pared to the placebo group (37.3%, 95% CI 31.6–43.0) at
12 months, although this was not significant (p = 0.20).
Figure 1 presents the Kaplan-Meier plot for the prob-
abilities of survival over the study period.
Of the 539 patients, only 292 (54%) had complete cost
and QALY data and could be included in the cost-utility
analysis; 153 in the simvastatin group and 139 in the
placebo. Death was not treated as a censoring event in
the cost-utility analysis and so patients were included in
the analysis if they had died and zero costs could be
assigned as detailed in the Methods section, or if they
had complete 6- and 12-month follow-up questionnaire
data (Fig. 2). Baseline characteristics of patients included
in the analysis were broadly similar between groups (see
Additional file 1), and similar to the baseline characteris-
tics of the original sample reported previously [6].
Patient use of health services within the categories of
primary hospital admission, other hospital, community
and care over the 12-month study period are presented
in Additional file 2. Mean costs for these categories at
6 months and 12 months were estimated and are pre-
sented in Table 2. There was a considerable amount of
variability in costs as reflected in the large standard devi-
ations (SDs). However, lower mean costs were observed
in the simvastatin group for all service categories except
for other hospital services from baseline to 6 months
with a total incremental cost of –£3601 indicating a
cost-saving in favour of simvastatin. The cost-saving was
largely driven by the higher mean number of ICU and
high-dependency unit bed days in the placebo group and
the high unit costs associated with them (Table 1). Post-
discharge, the most notable differences in costs were as-
sociated with care-related services. The analyses of re-
source and costs for all patients with available data and
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Fig. 1 Kaplan-Meier plot for probabilities of survival over the 12-month study period according to whether patients received simvastatin or placebo
Fig. 2 Patient drop out from the cost-utility analysis at 12 months. QALY quality-adjusted life year
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not just those included in the cost-utility analysis are
presented in Additional file 3. It is worth noting that, in
the analysis of all patients, primary admission data was
available for 532 patients and the difference in primary
admission costs was only –£293 (see Table S6 in
Additional file 3).
Health outcomes
The HRQoL of patients at 6 and 12 months (measured
using the EQ-5D-3L) and QALYs at 12 months are pre-
sented in Table 3. All patients were assigned the same
utility value at baseline (–0.402). There was little change
in the HRQoL of patients in both groups from 6 to
12 months, but the HRQoL was statistically significantly
higher in the simvastatin group at 6 months. The differ-
ence in QALYs (0.064) was also statistically significant.
The analysis of utilities and QALYs for all patients with
available data is presented in Additional file 3.
Results from the primary cost-utility analysis and the
sensitivity analyses are presented in Table 4. Since
simvastatin was both less costly and significantly more
effective than the placebo (in terms of QALYs) it can be
considered the dominant strategy. In this situation the
ICER would be negative and is therefore not calculated
as its magnitude does not convey any meaning [17].
Sampling uncertainty in the data is represented by the
joint distribution of the bootstrapped differences in cost
and QALY on the cost-effectiveness plane for the pri-
mary analysis (Fig. 3). The majority of the points lie
below the x axis indicating simvastatin is cost saving,
and to the right of the y axis indicating simvastatin pro-
duces more QALYs than placebo. The small number of
points lying outside of this area indicates a small degree
of variability surrounding the presence and magnitude
of cost-savings and effectiveness. The CEAC for the
primary analysis presented in Fig. 4 summarises this un-
certainty for the decision maker and presents the prob-
ability of simvastatin being cost-effective compared to
placebo at different thresholds of WTP per QALY gain
for the primary and sensitivity analyses. The CEAC for
the primary analysis indicates that, at a WTP threshold
of £20,000 per QALY gain, the probability of simvastatin
being cost-effective is 99%.
Sensitivity analyses were conducted to determine
the impact of changing particular assumptions on the
cost-effectiveness (Table 4). Although there are some
notable effects on differential mean costs and effects,
the CEACs for the sensitivity analyses Fig. 4 indicate
that cost-effectiveness of simvastatin was robust to
these changes in the assumptions, with the probability
of it being cost-effective at £20,000 per QALY never
dropping below 90%.
Table 2 Health services costs (UK £) over the study period by groupa
Service costs Simvastatin
n = 139
Placebo
n = 153
Difference (95% CI)b
simvastatin – placebo
Mean (SD) Mean (SD)
Baseline to 6 months
Primary admission 22,034.30 (14,673.67) 25,186.17 (20,202.18) –3151.87 (–7755.42 to 565.96)
Other hospital services 641.23 (2351.29) 604.92 (3978.81) 36.31 (–814.56 to 673.96)
Community health Services 279.29 (583.75) 341.42 (1087.34) –62.13 (–288.39 to 119.26)
Care-related services 186.71 (1065.18) 368.99 (1605.87) –182.28 (–501.60 to 139.83)
6 to 12 months
Other hospital services 604.81 (2387.51) 631.05 (3523.03) –26.24 (–784.03 to 570.07)
Community health services 229.97 (739.66) 231.66 (645.46) –1.69 (–159.67 to 151.49)
Care-related services 139.05 (1156.05) 352.05 (2353.14) –213.00 (–678.17 to 177.77)
Total baseline to 6 months 23,141.53 (15,469.09) 26,501.51 (21,474.96) –3359.98 (–8247.32 to 644.99)
Total 7–12 months 973.83 (3380.62) 1214.76 (5213.93) –240.93 (–1323.17 to 634.04)
Total 12-month health service costs 24,115.36 (17,154.86) 27,716.27 (23,643.97) –3600.91 (–8872.17 to 722.79)
a Sample sizes based on all patients with available data
b Confidence interval (CI) based on 1000 bootstrap resamples. Significance is judged when the confidence interval does not cross zero. Negative costs reflected
cost-savings in favour of the intervention
SD standard deviation
Table 3 Mean (SD) EQ-5D-3L utilities and QALYs, by treatment
group
Simvastatin
n = 139
Placebo
n = 153
Difference (95% CI)
simvastatin – placebo
Mean (SD) Mean (SD)
6 months utility 0.316 (0.373) 0.222 (0.348) 0.094 (0.012 to 0.175)
12 months utility 0.315 (0.375) 0.244 (0.371) 0.070 (–0.014 to 0.155)
QALYsa 0.136 (0.274) 0.072 (0.262) 0.064 (0.002 to 0.127)
a Calculated using baseline (–0.402, 6-, and 12-month utilities)
CI confidence interval, EQ-5D-3L EuroQol Five Dimension (Three Level), QALY
quality-adjusted life year, SD standard deviation
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Discussion
The results of the cost-utility analysis alongside the
HARP-2 trial indicate that simvastatin compared to
placebo was associated with lower costs and a signifi-
cant QALY gain. Whilst the gain in QALYs was small
(0.064; equivalent to 23 days of full health), it was as-
sociated with a cost saving equating to £3601 over
the 12-month period. Simvastatin has a very high
probability of being considered cost-effective at 1 year
and findings were robust to changes in the methodo-
logical assumptions.
There is currently no consensus on what constitutes a
minimally important difference in mean QALYs between
groups [19]; however, 0.05 has been suggested previously
[19, 20]. The difference observed in our analysis exceeds
this, suggesting the small difference is still meaningful.
The gain in QALYs corroborates with the modest bene-
fits observed in the clinical effectiveness analysis [6].
Since all patients were assigned the same utility score at
baseline, the difference in QALYs is due to the HRQoL
of simvastatin patients being higher than placebo at both
6 and 12 months.
Table 4 Incremental costs and QALYs (with 95% CI), associated incremental cost-effectiveness ratios, and the probability of simvastatin
being cost-effective compared to placebo at a threshold willingness to pay/QALY of £20,000 for the base case and sensitivity analyses
Analysis Incremental total health
service costs (UK £; 95% CIa)
Incremental QALY
gain (95% CIa)
Probability of cost-effectiveness
at £20,000 per QALY (%)
Primary analysis (unadjusted) (simvastatin n = 139,
placebo n = 153b)
–3600.91 (–8061.10 to 859.28) 0.064 (0.002 to 0.127) 99%
Adjusted for baseline variables (simvastatin n = 139,
placebo n = 153b)
–2661.03 (–7842.76 to 2520.70) 0.089 (0.025 to 0.151) 95%
Multiply imputed total costs and QALYs (simvastatin
n = 259, placebo n = 280c)
–2132.69 (–5629.21 to 1363.83) 0.042 (–0.001 to 0.086) 96%
Multiply imputed total costs and QALY, adjusted
(simvastatin n = 259, placebo n = 280c)
–1290.35 (–5000.61 to 2419.91) 0.048 (0.005 to 0.091) 90%
Death as a censoring event (simvastatin n = 74,
placebo n = 68b)
–8532.48 (–16107.75 to –957.21) 0.056 (–0.022 to 0.135) 99%
No mean imputation of care data (simvastatin
n = 137, placebo n = 151b)
–3966.00 (–8503.11 to 571.10) 0.066 (0.004 to 0.128) 99%
QALY calculation using discharge, 3-, 6-, and 12-month
EQ-5D-3 L (simvastatin n = 138, placebo n = 150b)
–3559.00 (–8241.41 to 1123.42) 0.084 (0.005 to 0.162) 99%
a Confidence intervals (CI) based on 1000 bootstrap resamples
b Sample sizes based on patients with complete data for both costs and quality-adjusted life years (QALYs)
c Sample sizes based on all patients since missing total costs and QALYs have been imputed
EQ-5D-3L EuroQol Five Dimension (Three Level)
Fig. 3 Cost-effectiveness plane for the primary cost-effectiveness analysis showing bootstrapped replications of mean incremental costs and quality-adjusted
life year (QALY) gain and the willingness-to-pay (WTP) threshold of £20,000/QALY
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The majority of differences in individual resource use
components were not statistically significant. However,
when costs were categorised as primary admission, other
hospital services, community health services, and care-
related services, differences were more apparent. The
largest difference in costs was related to patient stay in
primary admission and this was driven by the high cost
of ICU care. The majority of costs after discharge were
lower in the simvastatin group, with the most notable
cost savings associated with the primary admission. The
results corroborate with the HRQoL analysis; patients in
the placebo group experienced poorer health over the
study period and this appears to have impacted on their
use of health services after discharge
There were a number of limitations to the economic
evaluation. The study was powered to detect statistically
significant differences in the primary outcome and not
in costs, QALYs, or cost-effectiveness. However, this is
typically the case and significance rules are not typically
relied upon in the interpretation of cost-effectiveness
analyses [21] as greater emphasis is placed on the joint
distribution of cost and effects. Nonetheless, having a
sufficiently powered study would have led to more con-
clusive results [19] and allowed decision-makers to be
more confident in the value claim [17]. There are limita-
tions to this study related to the inevitable difficulties of
collecting follow-up data from patients recovering from a
stay in critical care. Previous intensive care trials [9, 10]
have also found it difficult to achieve high rates of long-
term data collection and the experience of HARP-2
confirms that this is a difficult population to follow-up.
Furthermore, economic data are particularly prone to
missing data due to the reliance on multiple components
within HRQoL and resource use questionnaires required
for the calculation of QALYs and costs. As a result, the
cost-utility analysis was performed on a subgroup of pa-
tients with complete cost and QALY data. Although the
baseline characteristics of the subgroup were observed to
be similar between study groups and similar to the ori-
ginal sample, the impact of this on primary admission
costs was notable; the mean difference increasing from –
£293 when all available data were used (n = 532) to –
£3152 for the subgroup (n = 292). This suggests that some
of the patients who were not included in the cost-utility
analysis were simvastatin patients who had incurred high
primary admission costs. It is important to highlight,
however, that multiple imputation of missing data was
performed using primary admission costs as one of the
predictors of missingness, and the cost-effectiveness of
simvastatin remained high.
The utilities derived from the discharge and 3-month
EQ-5D-3L were not used in the QALY calculation for
the primary analysis. This was due to the variable timing
of the discharge questionnaire and the 3-month ques-
tionnaire not being consistently administered to survi-
vors if they were still hospital in-patients. A sensitivity
analysis included them in the QALY calculation when
they were available and there was minimal impact on
the overall results. The probability of simvastatin being
cost-effectiveness at a WTP of £20,000 remained at 99%.
A key strength of this study is the successful long-
term follow-up of patients who have been discharged
from critical care to assess their survival, HRQoL, and
resource use. The results highlight the importance of
Fig. 4 Cost-effectiveness acceptability curves showing the probability of simvastatin being cost-effective compared to placebo for the primary and
sensitivity analyses. EQ-5D-3L EuroQol Five Dimension (Three Level), QALY quality-adjusted life year
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undertaking a health economic analysis in the setting where
the primary clinical outcome is not significantly different
between the trial arms. In addition, it flags important issues
regarding the use of short-term clinical outcomes such as
VFDs which have been shown to poorly correlate with
long-term patient-centred outcomes such as long-term
mortality [22] and QALYs [22, 23]. HARP-2 achieved a
non-significant 5% reduction in mortality, and the cost-
utility analysis found a significant QALY gain with a non-
significant cost saving at 12 months, but the trial is consid-
ered a negative trial due to the absence of a significant dif-
ference in the primary outcome (VFDs) at 28 days. In the
setting of no significant difference in mortality or other
clinical outcomes it is unlikely that the results of the cost-
effectiveness analysis will be sufficient to change clinical
practice. Had the trial been powered sufficiently for long-
term mortality or QALYs a different conclusion may have
been reached. QALYs may be a feasible patient-centred pri-
mary outcome for critical care studies as they combine both
morbidity and mortality, and have potential gains in statis-
tical power due to being a continuous variable [20].
Conclusions
Simvastatin was found to be cost-effective at 1 year com-
pared to placebo for the treatment of ARDS, being associ-
ated with both a significant QALY gain and cost saving.
The cost-effectiveness remained robust to changes in meth-
odological assumptions. However, given that the health
economic analysis was performed on a subgroup of patients
and the QALY gain was relatively small, there are currently
insufficient data to support the treatment of patients with
ARDS with simvastatin in the NHS.
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